Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Joris Hemelaar, University Research Lecturer and expert in maternal HIV infection at the Nuffield Department of Women's & Reproductive Health, published a new article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015" in the Lancet HIV.

Dr Joris Hemelaar, University Research Lecturer and expert in maternal HIV infection at the Nuffield Department of Women's & Reproductive Health, has published a new article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015" in the Lancet HIV.

Global HIV-1 genetic diversity and evolution form a major challenge to treatment and prevention efforts. An increasing number of distinct HIV-1 recombinants have been identified worldwide (106 distinct recombinants to date), but their contribution to the global epidemic was hitherto unknown.

Dr Hemelaar's article: "Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey" is the first study to describe the global and regional distribution of HIV-1 recombinants (viruses that are the result of a cross-over between two or more different strains of HIV). This study is based on nearly 400,000 HIV samples covering the period 1990 to 2015. The global and regional distribution of HIV-1 recombinants was found to be extremely diverse and evolve over time. The number and proportion of recombinants is increasing worldwide, reaching 22.8% of global HIV-1 infections in 2010-2015. Recombinants play prominent roles in several regions, including in sub-Saharan Africa, East and South-east Asia, Middle East and North Africa, Eastern Europe and central Asia, and Latin America. This demonstrates the way the HIV pandemic is evolving and highlights the increasing challenge facing the development of a globally effective HIV vaccine as well as the need for ongoing adaptation of HIV diagnostic, drug resistance, and viral load assays.

Read the full article here.

The increasing genetic diversity of the HIV pandemic has important implications for HIV transmission and pathogenesis, diagnosis, treatment and drug resistance, as well as the immune response to HIV. Ongoing recombination necessitates continued and improved surveillance of the global molecular epidemiology of HIV-1 to inform the design of an HIV vaccine and the development of viral assays, which are crucial to achieving the UNAIDS 90:90:90 treatment targets.

"An evolving genetic tapestry of HIV-1 recombinants" - is the comment in response to Dr Hemelaar's Lancet article, which can be read here. 

The article and comment are published in the November issue of The Lancet HIV here.

Find out more about the global research of Dr Joris Hemelaar here.